Oncology
|
October 22, 2024

Lab Tests For Patients With A Family History of Breast Cancer

Medically Reviewed by
Updated On
October 31, 2024

Breast cancer affects many lives, with 1 in 8 women in the U.S. facing a diagnosis at some point in their life. Those with a family history are at an even higher risk, as approximately 5% to 10% of cases are believed to be hereditary. Early detection can make a meaningful difference, potentially improving treatment options and health outcomes.

This article discusses essential lab tests recommended for individuals with a family history of breast cancer. It aims to equip healthcare providers and patients with information to make informed decisions and proactively manage the disease.

[signup]

[46]

Understanding the Role of Family History in Breast Cancer Risk

Family history is a crucial aspect of breast cancer risk, which requires looking more closely at genetic factors and important statistics.

Genetic Linkage and Statistics

Family history increases breast cancer risk mainly through inherited genetic mutations and common environmental factors.

A woman's risk of developing breast cancer doubles if she has a first-degree relative—such as her mother, sister, or daughter—who has been diagnosed with the disease.

These statistics emphasize the significant influence of family history on breast cancer risk. This increased risk is often linked to genetic mutations like the BRCA1 and BRCA2 genes.

Family history may also reflect shared lifestyle choices and environmental influences, including diet or exposure to certain toxins, which can also play a role in cancer risk.

In addition to family history, other factors such as age, reproductive history, and lifestyle choices also affect an individual's overall risk.

[39]

Genetic Testing for Breast Cancer Risk

There are several genes associated with breast cancer.

BRCA1 and BRCA2 Mutation Testing

Approximately 15% of women with a breast cancer diagnosis have a family member with the same diagnosis, often linked to BRCA1 and BRCA2 mutations.

These mutations may affect the body’s ability to repair DNA, potentially increasing the risk of breast cancer. Over 60% of women with a harmful mutation in the BRCA1 or BRCA2 genes are likely to develop breast cancer during their lifetime.

Genetic testing for BRCA mutations may be beneficiall for individuals with a family history of breast cancer, especially if multiple relatives have been affected or if they were diagnosed at a young age.

Interpretation of Results

If you choose to undergo genetic testing, bear in mind that interpreting results can be challenging. Generally, genetic test results indicate whether you have a mutation linked to breast cancer or other cancers. Let's take a closer look:

  • A positive BRCA test result suggests a mutation that may increase the risk of developing breast cancer.
  • A negative result suggests the individual does not carry the mutations, but it's important to remember that other factors can still contribute to overall risk.
  • The testing might also identify a ‘variant of uncertain significance,’ indicating a change in the BRCA gene that requires further research to better understand its potential impact on breast cancer risk.

PALB2, TP53, and Other Gene Mutations

While most people are familiar with BRCA1 and BRCA2, other genes, such as PALB2 and TP53, can also increase breast cancer risk.

Research shows that women with a mutation in the PALB2 gene have a 35% higher likelihood of a breast cancer diagnosis by age 70 compared to those without the mutation. TP53 is linked to Li-Fraumeni syndrome, which raises the risk for cancer, including breast cancer.

Testing for additional gene mutations may be useful for individuals with a family history of breast cancer who test negative for BRCA mutations, particularly in families with early-onset cases or multiple cancers among relatives.

[62]

Hormone Receptor and HER2 Testing

Understanding hormone receptor and human epidermal growth factor receptor 2 (HER2) status is essential for guiding breast cancer treatment, especially for those with a family history of the disease.

Estrogen Receptor (ER) and Progesterone Receptor (PR) Testing

Hormone receptors are proteins on or inside cells that bind to hormones, triggering changes that affect cell growth and function.

In breast cancer, the key hormone receptors are:

  • Estrogen Receptors (ER): These bind to estrogen and can stimulate the growth of some breast cancer cells.
  • Progesterone Receptors (PR): These bind to progesterone and can also influence breast cancer growth.

Hormone receptor status tells us if breast cancer cells have proteins that attach to estrogen or progesterone hormones. This information can provide insights into potential treatment response and help guide healthcare decisions.

Hormone receptor-positive cancers (HR+) may respond to hormone therapy, potentially improving health outcomes.

Individuals with a family history of breast cancer, especially first-degree relatives diagnosed with the disease, should consider hormone receptor testing. This testing guides treatment options, assesses personal risk, and helps patients make informed decisions.

HER2/neu Testing

HER2 testing measures the human epidermal growth factor receptor 2 (HER2) protein levels in cancer cells. When an excess of HER2 is present on the surface of breast cancer cells, this is referred to as HER2 protein overexpression. 

This condition occurs in approximately 15–30% of breast cancers and is linked to more aggressive forms of the disease that grow and spread more rapidly. HER2-positive cancers may not respond as well to hormone treatments, and often require targeted approaches.

If a tumor is HER2-positive, it indicates a higher risk of recurrence and informs doctors on the most effective treatment strategies. HER2-positive cancers often need targeted therapies to improve outcomes. Identifying HER2 overexpression can help healthcare providers recommend targeted interventions.

Imaging and Blood-Based Biomarker Testing

Imaging and blood tests are important tools for understanding risk and monitoring progress when considering tools for breast cancer detection.

Breast MRI for High-Risk Patients

Breast MRI is often the preferred imaging method for patients with a strong family history of breast cancer due to its higher sensitivity in detecting abnormalities compared to mammography.

A recent study indicated that MRI is more effective at detecting breast cancer, especially considering the potential risks associated with repeated X-ray exposure. This meta-analysis of 18 studies involving 1,000 women found that MRI alone detected 8 more cases of breast cancer than a mammogram.

While combining MRI with mammography slightly improved detection rates, MRI alone was shown to be effective in this study, suggesting it may offer valuable insights for women at higher risk for breast cancer.

Circulating Tumor Cells (CTCs) and DNA (ctDNA) Tests

Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) tests are advanced blood tests that detect cancer cells or tumor DNA in the bloodstream. These tests are helpful for high-risk patients because they can signal early detection of cancer recurrence or progression before traditional imaging and often before clinical symptoms appear.

Research suggests that CTCs and ctDNA may offer promising non-invasive insights in breast health monitoring. These tests may provide early insights into a patient’s health status, potentially supporting timely healthcare adjustments. However, more research is needed before they can be used in routine clinical care.

Routine and Additional Blood Tests for Risk Assessment

Taking care of your health involves regular check-ups and specific blood tests, especially for those with a family history of breast cancer.

CA 15-3 and CA 27-29 Tumor Markers

CA 15-3 and CA 27-29 are blood tests used as tumor markers for breast cancer. They measure specific proteins that can be elevated when breast cancer is present. 

While they are not used for initial diagnosis, these tests may be helpful for monitoring, particularly for individuals with a history of breast cancer or those considered higher risk. 

Additionally, these tests can help with early detection in patients with a family history of breast cancer.

Complete Blood Count (CBC) and Liver Function Tests (LFTs)

A Complete Blood Count (CBC) and Liver Function Tests (LFTs) are routine blood tests that measure general health markers. They are important because they may help healthcare providers understand general health and identify potential issues requiring further evaluation.

  •  A CBC measures components of your blood, including red and white blood cells and platelets. Abnormal levels can indicate conditions such as anemia, infection, or blood disorders, which may suggest malignancy or metastasis.
  • LFTs assess how well your liver functions by measuring enzymes (AST, ALT) and proteins produced by the liver. Elevated levels can indicate liver damage or disease, possibly caused by metastasis or cancer spread.

Why These Tests Matter

For patients with a family history of breast cancer, these tests may provide helpful insights into overall health and can support early identification of potential health issues.

How Healthcare Providers Can Guide Patients

Healthcare providers can support patients by creating personalized testing plans based on individual risk factors.

Importance of Personalized Testing Plans

Personalized testing plans can be beneficial for individuals at high risk for breast cancer, especially those with a family history. This approach may support timely health assessments.

To accurately assess individual risk, healthcare providers should take a comprehensive approach that includes:

  • Detailed Family History: Focus on first-degree (mother, sister, daughter) and second-degree relatives (aunt, grandmother) to identify hereditary patterns such as BRCA1 and BRCA2 mutations.
  • Genetic Counseling: Refer high-risk patients to genetic counselors for evaluations and targeted testing to assess the likelihood of hereditary cancer syndromes.
  • Personal Medical History: Consider prior biopsies and benign breast conditions, as these can elevate risk.
  • Lifestyle Factors: Assess age, body mass index (BMI), alcohol consumption, and reproductive history, as these can influence overall risk.
  • Risk Assessment Tools: To quantify risk and allow for a more objective evaluation, use established models like the Gail Model or the Tyrer-Cuzick Model.

Recommending Appropriate Testing

Once individual risk is assessed, healthcare providers can recommend testing strategies:

  • Timing of Screenings: For high-risk individuals, guidelines may suggest initiating screenings earlier, often at age 30 or 10 years before a relative's diagnosis.
  • Types of Screenings: Combine mammograms with MRI screenings may provide greater sensitivity in assessing breast health for early signs of concern.
  • Frequency of Screenings: Outline individualized screening intervals based on risk, which could include semi-annual assessments as appropriate.
  • Monitoring Changes: Regularly revisit and adjust testing plans based on new information or changes in risk.

Shared Decision-Making

Collaboration between healthcare practitioners and patients is vital for determining effective testing strategies. Shared decision-making promotes open communication, letting patients express their concerns and preferences. Providers can explain the benefits and limitations of different screening options, helping patients understand how each choice may impact their overall health approach.

This approach helps patients feel supported, informed, and heard, encouraging a proactive attitude toward their healthcare. By prioritizing shared decision-making, providers build trust and promote active patient engagement, ultimately improving adherence to screening recommendations.

[signup]

Key Takeaways

  • Individuals with a family history of breast cancer may benefit from essential lab tests to understand their risk and improve early detection.
  • These labs include:
    • Genetic testing for BRCA1, BRCA2, and other relevant gene mutations
    • Hormone receptor and HER2 testing
    • Advanced imaging options like breast MRI
    • Blood tests for tumor markers such as CA 15-3 and CA 27-29
  • Patients and healthcare providers are encouraged to discuss risk factors and available screening options openly. This collaboration can lead to personalized testing plans that improve outcomes for those at higher risk of breast cancer.
The information provided is not intended to be a substitute for professional medical advice. Always consult with your doctor or other qualified healthcare provider before taking any dietary supplement or making any changes to your diet or exercise routine.

Learn more

No items found.

Lab Tests in This Article

No lab tests!

References

  1. American Cancer Society. (2021a, November 8). Breast Cancer Hormone Receptor Status | Estrogen Receptor. Www.cancer.org. https://www.cancer.org/cancer/types/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-hormone-receptor-status.html
  2. American Cancer Society. (2021b, December 16). Breast Cancer Risk Factors You Can't Change. Www.cancer.org. https://www.cancer.org/cancer/types/breast-cancer/risk-and-prevention/breast-cancer-risk-factors-you-cannot-change.html
  3. American Cancer Society. (2023, December 19). ACS breast cancer screening guidelines. Www.cancer.org. https://www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html
  4. Antoniou, A. C., Casadei, S., Heikkinen, T., Barrowdale, D., Pylkäs, K., Roberts, J., Lee, A., Subramanian, D., De Leeneer, K., Fostira, F., Tomiak, E., Neuhausen, S. L., Teo, Z. L., Khan, S., Aittomäki, K., Moilanen, J. S., Turnbull, C., Seal, S., Mannermaa, A., & Kallioniemi, A. (2014). 
  5. Alanine Aminotransferase. (n.d.). Rupa Health. https://www.rupahealth.com/biomarkers/alt
  6. Aspartate Aminotransferase. (n.d.). Rupa Health. https://www.rupahealth.com/biomarkers/ast
  7. Breast-Cancer Risk in Families with Mutations in PALB2. New England Journal of Medicine, 371(6), 497–506. https://doi.org/10.1056/nejmoa1400382
  8. Basic Laboratory Markers Testing. (n.d.). Rupa Health. https://www.rupahealth.com/health-categories/basic-laboratory-markers
  9. Blake, K. (2023, December 15). The Power of Functional Foods in Cancer Prevention. Rupa Health. https://www.rupahealth.com/post/the-power-of-functional-foods-in-cancer-prevention
  10. BRCA Gene Mutations: Cancer Risk and Genetic Testing Fact Sheet - NCI. (2024 19). Www.cancer.gov. https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet#what-do-brca1-and-brca2-genetic-test-results-mean
  11. BRCA Genetic Test: MedlinePlus Medical Test. (2020, June). Medlineplus.gov. https://medlineplus.gov/lab-tests/brca-test/
  12. Breast Cancer Facts and Statistics. (2022, March 10). Www.breastcancer.org. https://www.breastcancer.org/facts-statistics
  13. Brewer, H. R., Jones, M. E., Schoemaker, M. J., Ashworth, A., & Swerdlow, A. J. (2017). Family history and risk of breast cancer: an analysis accounting for family structure. Breast Cancer Research and Treatment, 165(1), 193–200. https://doi.org/10.1007/s10549-017-4325-2
  14. CA 27-29. (n.d.). Stanfordhealthcare.org. https://stanfordhealthcare.org/medical-tests/t/tumor-markers/types/ca-27-29.html
  15. Casaubon, J. T., Grewal, U. S., & Regan, J.-P. (2020). BRCA 1 and 2 Mutations. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK470239/
  16. Centers for Disease Control and Prevention. (2024a, March 11). Breast cancer risk factors. Breast Cancer. https://www.cdc.gov/breast-cancer/risk-factors/index.html
  17. Centers for Disease Control and Prevention. (2024b, May 17). What Causes Hereditary Breast and Ovarian Cancers. Hereditary Breast and Ovarian Cancer. https://www.cdc.gov/breast-ovarian-cancer-hereditary/causes/index.html
  18. Christie, J. (2024, October 9). The Essential Guide to Mammograms: Supporting Your Health with Early Detection. Rupa Health. https://www.rupahealth.com/post/the-essential-guide-to-mammograms-supporting-your-health-with-early-detection
  19. Clough, K. (2023, October 24). Progesterone Power: The Unsung Heroine in Women's Health and Mood. Rupa Health. https://www.rupahealth.com/post/progesterone-power-the-unsung-heroine-in-womens-health-and-mood
  20. Cloyd, J. (2023a, February 1). 6 anemia types you need to know about. Rupa Health. https://www.rupahealth.com/post/6-different-types-of-anemia-you-may-not-be-aware-of
  21. Cloyd, J. (2023b, July 7). Integrative Approaches to Reducing Toxin Exposure in Everyday Life. Rupa Health. https://www.rupahealth.com/post/integrative-approaches-to-reducing-toxin-exposure-in-everyday-life
  22. Cloyd, J. (2023c, December 1). How to Interpret CBC Results: A Comprehensive Guide. Rupa Health. https://www.rupahealth.com/post/how-to-interpret-cbc-results-a-comprehensive-guide
  23. Cloyd, J. (2024a, January 22). Interpreting Liver Enzyme Tests: ALT, AST, and ALP in Liver Health Monitoring. Rupa Health. https://www.rupahealth.com/post/interpreting-liver-enzyme-tests-alt-ast-and-alp-in-liver-health-monitoring
  24. Cloyd, J. (2024, March 15). 4 Decisive Signs You Need Hormone Replacement Therapy. Rupa Health. https://www.rupahealth.com/post/signs-you-need-hormone-replacement-therapy
  25. Daly, M. B., Pal, T., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., Elkhanany, A., Friedman, S., Goggins, M., Hutton, M. L., Karlan, B. Y., Khan, S., Klein, C., Kohlmann, W., Kurian, A. W., Laronga, C., Litton, J. K., Mak, J. S., Menendez, C. S., & Merajver, S. D. (2021). Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 19(1), 77–102. https://doi.org/10.6004/jnccn.2021.0001
  26. DeCesaris, L. (2023, May 4). Epigenetic Insights: A Guide to Utilizing Epigenetic Testing for Optimal Patient Outcome. Rupa Health. https://www.rupahealth.com/post/how-to-use-epigenetic-testing-for-best-patient-outcomes
  27. DeCesaris, L. (2024, January 9). Maximizing patient engagement: Innovative strategies for functional medicine practices. Rupa Health. https://www.rupahealth.com/post/maximizing-patient-engagement-innovative-strategies-for-functional-medicine-practices
  28. Ding, W., Fan, Z., Xu, Y., Wei, C., Li, Z., Lin, Y., Zhu, J., & Ruan, G. (2023). Magnetic resonance imaging in screening women at high risk of breast cancer: A meta-analysis. Medicine, 102(10), e33146. https://doi.org/10.1097/MD.0000000000033146
  29. Effat Alemzadeh, Allahqoli, L., Dehghan, H., Afrooz Mazidimoradi, Alireza Ghasempour, & Hamid Salehiniya. (2023). Circulating tumor cells and circulating tumor DNA in breast cancer diagnosis and monitoring. Oncology Research, 31(5), 667–675. https://doi.org/10.32604/or.2023.028406
  30. Estrogen Receptor, Progesterone Receptor Tests: MedlinePlus Medical Test. (2020, June 24). Medlineplus.gov. https://medlineplus.gov/lab-tests/estrogen-receptor-progesterone-receptor-tests/
  31. Family History. (2023, November 14). Www.breastcancer.org. https://www.breastcancer.org/risk/risk-factors/family-history
  32. Find Cancer Early | American Cancer Society. (n.d.). Www.cancer.org. https://www.cancer.org/cancer/screening.html
  33. Genetic Mutations in Humans. (2022, May 24). Cleveland Clinic; Cleveland Clinic. https://my.clevelandclinic.org/health/body/23095-genetic-mutations-in-humans
  34. Gunduru, M., & Grigorian, C. (2020). Breast Magnetic Resonance Imaging (MRI). PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK539727/
  35. Gutierrez, C., & Schiff, R. (2011). HER2: biology, detection, and Clinical Implications. Archives of Pathology & Laboratory Medicine, 135(1), 55–62. https://doi.org/10.1043/2010-0454-RAR.1
  36. Hepatic Testing. (n.d.). Rupa Health. https://www.rupahealth.com/health-categories/hepatic
  37. HER2 Status. (2024, September 20). Www.breastcancer.org. https://www.breastcancer.org/pathology-report/her2-status
  38. HER2 Tumor Marker Test: MedlinePlus Medical Test. (2024, June). Medlineplus.gov. https://medlineplus.gov/lab-tests/her2-tumor-marker-test/
  39. Hereditary and Familial Cancer. (2023, November 4). Angel M - Marlene van Staden Breast Cancer Awareness Foundation. https://angelm.org.za/cancer-info/
  40. Himes, D. O., Root, A. E., Gammon, A., & Luthy, K. E. (2016). Breast Cancer Risk Assessment: Calculating Lifetime Risk Using the Tyrer-Cuzick Model. The Journal for Nurse Practitioners, 12(9), 581–592. https://doi.org/10.1016/j.nurpra.2016.07.027
  41. Holt, E., & Peerey, H. (2022). Hormone Receptor - an overview | ScienceDirect Topics. Sciencedirect.com. https://www.sciencedirect.com/topics/neuroscience/hormone-receptor
  42. Iqbal, N., & Iqbal, N. (2014). Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Molecular Biology International, 2014(1), 1–9. https://doi.org/10.1155/2014/852748
  43. Johns Hopkins Medicine. (n.d.). Breast Magnetic Resonance Imaging (MRI). Www.hopkinsmedicine.org. https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/breast-mri
  44. Khakham, C. (2023, July 10). Understanding Environmental Toxins and Their Impact on Health. Rupa Health. https://www.rupahealth.com/post/understanding-environmental-toxins-and-their-impact-on-health
  45. Li-Fraumeni Syndrome: Definition, Symptoms & Outlook. (2021, August 11). Cleveland Clinic. https://my.clevelandclinic.org/health/diseases/22073-li-fraumeni-syndrome
  46. Liu, D. (2019, July 18). Breast Cancer. Cancer Treatment Centers of America. https://www.cancercenter.com/cancer-types/breast-cancer/risk-factors
  47. Lyman, G. H., Greenlee, H., Bohlke, K., Bao, T., DeMichele, A. M., Deng, G. E., Fouladbakhsh, J. M., Gil, B., Hershman, D. L., Mansfield, S., Mussallem, D. M., Mustian, K. M., Price, E., Rafte, S., & Cohen, L. (2018). Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline. Journal of Clinical Oncology, 36(25), 2647–2655. https://doi.org/10.1200/jco.2018.79.2721
  48. Maholy, N. (2023, March 16). Integrative Medicine Approach to Estrogen Excess: Testing, Diagnosis, & Treatment. Rupa Health. https://www.rupahealth.com/post/integrative-medicine-approach-to-estrogen-excess-testing-diagnoses-treatment
  49. Malani, S. (2023a, March 8). What is Integrative Oncology and How Can it Help Your Cancer Journey? Rupa Health. https://www.rupahealth.com/post/what-is-integrative-oncology-and-how-can-it-help-your-cancer-journey
  50. Malani, S. (2023b, April 17). An Integrative Medicine Approach to Breast Cancer Prevention. Rupa Health. https://www.rupahealth.com/post/an-integrative-medicine-approach-to-breast-cancer-prevention
  51. Malani, S. (2023c, May 2). Complementary and Integrative Testing, Therapies, and Treatment and Recovery of Breast Cancer. Rupa Health. https://www.rupahealth.com/post/complementary-integrative-therapies-for-treatment-and-recovery-of-breast-cancer
  52. Malani, S. (2023d, June 28). Complementary and Integrative Medicine Treatment for Cancer Related Fatigue. Rupa Health. https://www.rupahealth.com/post/functional-medicine-labs-that-can-help-individualize-treatment-for-patients-with-cancer-related-fatigue-crf
  53. Malignant Neoplasm: What It Is, Types & Factors. (2022, February 1). Cleveland Clinic. https://my.clevelandclinic.org/health/diseases/22319-malignant-neoplasm
  54. Manahan, E. R., Kuerer, H. M., Sebastian, M., Hughes, K. S., Boughey, J. C., Euhus, D. M., Boolbol, S. K., & Taylor, W. A. (2019). Consensus Guidelines on Genetic Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons. Annals of Surgical Oncology, 26(10), 3025–3031. https://doi.org/10.1245/s10434-019-07549-8
  55. Mayo Clinic. (2019). Breast MRI - Mayo Clinic. Mayoclinic.org. https://www.mayoclinic.org/tests-procedures/breast-mri/about/pac-20384809
  56. Mayo Clinic. (2023, January 14). Complete Blood Count (CBC). Mayo Clinic. https://www.mayoclinic.org/tests-procedures/complete-blood-count/about/pac-20384919
  57. Medline Plus. (2020, August 18). TP53 gene: MedlinePlus Genetics. Medlineplus.gov. https://medlineplus.gov/genetics/gene/tp53/
  58. MedlinePlus. (2019). Liver Function Tests: MedlinePlus Lab Test Information. Medlineplus.gov. https://medlineplus.gov/lab-tests/liver-function-tests/
  59. National Cancer Institute. (2019a). Breast Cancer Risk Assessment Tool. Breast Cancer Risk Assessment Tool. https://bcrisktool.cancer.gov/
  60. National Cancer Institute. (2019). Breast Cancer Screening | Cancer Trends Progress Report. Cancer.gov. https://progressreport.cancer.gov/detection/breast_cancer
  61. New ACR Breast Cancer Screening Guidelines call for earlier screening for high-risk women. (2023, May). Www.acr.org. https://www.acr.org/Media-Center/ACR-News-Releases/2023/New-ACR-Breast-Cancer-Screening-Guidelines-call-for-earlier-screening-for-high-risk-women
  62. Peleg Hasson, S., Menes, T., & Sonnenblick, A. (2020). Comparison of Patient Susceptibility Genes Across Breast Cancer: Implications for Prognosis and Therapeutic Outcomes. Pharmacogenomics and Personalized Medicine, Volume 13, 227–238. https://doi.org/10.2147/pgpm.s233485
  63. Petrucelli, N., Daly, M. B., & Pal, T. (2023, September 21). BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer. Nih.gov; University of Washington, Seattle. https://www.ncbi.nlm.nih.gov/books/NBK1247/
  64. Platelets. (n.d.). Rupa Health. https://www.rupahealth.com/biomarkers/platelets
  65. Polygenic Risk Score - Breast Cancer | Rupa Health. (2020). Rupa Health. https://www.rupahealth.com/biomarkers/polygenic-risk-score-breast-cancer
  66. Powers, J. (2024, September 4). Getting Genetic Test Results. Www.breastcancer.org. https://www.breastcancer.org/genetic-testing/getting-results
  67. Preston, J. (2023a, March 9). 7 most common female reproductive health issues. Rupa Health. https://www.rupahealth.com/post/7-most-common-female-reproductive-health-issues
  68. Preston, J. (2023b, March 21). The Impact of Diet on Women's Health. Rupa Health. https://www.rupahealth.com/post/the-impact-of-diet-on-womens-health
  69. Preston, J. (2023c, August 16). A Comprehensive Approach to Fibrocystic Breasts: Testing and Getting to The Root Cause. Rupa Health. https://www.rupahealth.com/post/a-comprehensive-approach-to-fibrocystic-breasts
  70. Red Blood Cells. (n.d.). Rupa Health. https://www.rupahealth.com/biomarkers/rbc
  71. Rossi, C., Maggiore, C., Rossi, M. M., Filippone, A., Guarino, D., Di Micco, A., Forcina, L., & Magno, S. (2021). A Model of an Integrative Approach to Breast Cancer Patients. Integrative Cancer Therapies, 20, 153473542110408. https://doi.org/10.1177/15347354211040826
  72. Ryu, J. M., Kang, D., Cho, J., Lee, J. E., Kim, S. W., Nam, S. J., Lee, S. K., Kim, Y. J., Im, Y.-H., Ahn, J. S., Park, Y. H., Kim, J.-Y., Lee, H., Kang, M., & Yu, J. H. (2023). Prognostic Impact of Elevation of Cancer Antigen 15-3 (CA15-3) in Patients With Early Breast Cancer With Normal Serum CA15-3 Level. Journal of Breast Cancer, 26(2), 126. https://doi.org/10.4048/jbc.2023.26.e17
  73. Shockney, L. (2024, October 8). Risk Factors. National Breast Cancer Foundation. https://www.nationalbreastcancer.org/breast-cancer-risk-factors/
  74. Vidlarova, M., Rehulkova, A., Stejskal, P., Prokopova, A., Slavik, H., Hajduch, M., & Srovnal, J. (2023). Recent Advances in Methods for Circulating Tumor Cell Detection. International Journal of Molecular Sciences, 24(4), 3902–3902. https://doi.org/10.3390/ijms24043902
  75. What is circulating tumor DNA and how is it used to diagnose and manage cancer?: MedlinePlus Genetics. (2020, June). Medlineplus.gov. https://medlineplus.gov/genetics/understanding/testing/circulatingtumordna/
  76. What You Need to Know About the PALB2 Breast Cancer Gene. (2021, October 21). Medicine.yale.edu. https://medicine.yale.edu/news-article/what-you-need-to-know-about-the-palb2-breast-cancer-gene/
  77. When to Order a Breast MRI. (2024). Hopkinsmedicine.org. https://www.hopkinsmedicine.org/imaging/provider-information/order-wisely/when-to-order-breast-mri
  78. White Blood Cells. (n.d.). Rupa Health. https://www.rupahealth.com/biomarkers/wbc
  79. Yoshimura, H. (2023a, April 26). Complementary and Integrative Medicine Approaches to Oncology in Gerontology. Rupa Health. https://www.rupahealth.com/post/complementary-and-integrative-medicine-approaches-to-oncology-in-gerontology
  80. Yoshimura, H. (2023b, October 12). Top 4 Herbs For Liver Health and How to Use Them: An Evidence-Based Approach. Rupa Health. https://www.rupahealth.com/post/top-4-herbs-for-liver-health-and-how-to-use-them-an-evidence-based-approach
  81. Yoshimura, H. (2023c, October 19). What is alcohol-related liver disease, and how can functional medicine help? Rupa Health. https://www.rupahealth.com/post/what-is-alcohol-related-liver-disease-and-how-can-functional-medicine-help
  82. Yoshimura, H. (2023d, October 23). How to Support Your Liver Health With Nutritional Interventions in Functional Medicine. Rupa Health. https://www.rupahealth.com/post/nutritional-interventions-in-functional-medicine-for-liver-support
  83. Yoshimura, H. (2023e, December 11). Personalized Nutrition: Tailoring Diet Plans to Genetic Profiles. Rupa Health. https://www.rupahealth.com/post/personalized-nutrition-tailoring-diet-plans-to-genetic-profiles
  84. Yoshimura, H. (2024a, January 11). Hormone Replacement Therapy After Menopause and Cancer Risk: What The Evidence Says. Rupa Health. https://www.rupahealth.com/post/hormone-replacement-therapy-after-menopause-and-cancer-risk-what-the-evidence-says
  85. Yoshimura, H. (2024b, February 27). Exploring collaborative opportunities between functional medicine and conventional medical practitioners. Rupa Health. https://www.rupahealth.com/post/exploring-collaborative-opportunities-between-functional-medicine-and-conventional-medical-practitioners
  86. Yoshimura, H. (2024c, April 16). The effects of alcohol and caffeine on sleep: How to enjoy wisely. Rupa Health. https://www.rupahealth.com/post/the-effects-of-alcohol-and-caffeine-on-sleep-how-to-enjoy-wisely
Kristin Robinson
Author
Dr. Kristin Robinson ND
Naturopathic Doctor
Medically Reviewed by
Order from 30+ labs in 20 seconds (DUTCH, Mosaic, Genova & More!)
We make ordering quick and painless — and best of all, it's free for practitioners.
Sign up free
Browse the lab catalog

Latest Articles

View more on Oncology
A Comprehensive Guide to Lamotrigine Side EffectsA Comprehensive Guide to Lamotrigine Side Effects
A Comprehensive Guide to Lamotrigine Side Effects
,
November 20, 2024
Ayesha Bryant
Ayesha Bryant, MSPH, MD
November 20, 2024
How Lowering Salt Intake Could Help with Atopic DermatitisHow Lowering Salt Intake Could Help with Atopic Dermatitis
How Lowering Salt Intake Could Help with Atopic Dermatitis
,
November 19, 2024
Ayesha Bryant
Ayesha Bryant, MSPH, MD
November 19, 2024
Advanced Immune Cell Therapy Shows Promise in Treating Lupus NephritisAdvanced Immune Cell Therapy Shows Promise in Treating Lupus Nephritis
Advanced Immune Cell Therapy Shows Promise in Treating Lupus Nephritis
,
November 19, 2024
Ayesha Bryant
Ayesha Bryant, MSPH, MD
November 19, 2024
Turkey Tail Mushroom: Health Benefits & How to Use ItTurkey Tail Mushroom: Health Benefits & How to Use It
Turkey Tail Mushroom: Health Benefits & How to Use It
Dr. Emilie Wilson, ND, L.Ac.
November 19, 2024
Dr. ,
November 19, 2024
See all Articles
Subscribe to the Magazine for free
Subscribe for free to keep reading! If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Subscribe to the Magazine for free to keep reading!
Subscribe for free to keep reading, If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Trusted Source
Rupa Health
Medical Education Platform
Visit Source
Visit Source
American Cancer Society
Foundation for Cancer Research
Visit Source
Visit Source
National Library of Medicine
Government Authority
Visit Source
Visit Source
Journal of The American College of Radiology
Peer Reviewed Journal
Visit Source
Visit Source
National Cancer Institute
Government Authority
Visit Source
Visit Source
World Health Organization (WHO)
Government Authority
Visit Source
Visit Source
The Journal of Pediatrics
Peer Reviewed Journal
Visit Source
Visit Source
CDC
Government Authority
Visit Source
Visit Source
Office of Dietary Supplements
Government Authority
Visit Source
Visit Source
National Heart Lung and Blood Institute
Government Authority
Visit Source
Visit Source
National Institutes of Health
Government Authority
Visit Source
Visit Source
Clinical Infectious Diseases
Peer Reviewed Journal
Visit Source
Visit Source
Brain
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Rheumatology
Peer Reviewed Journal
Visit Source
Visit Source
Journal of the National Cancer Institute (JNCI)
Peer Reviewed Journal
Visit Source
Visit Source
Journal of Cardiovascular Magnetic Resonance
Peer Reviewed Journal
Visit Source
Visit Source
Hepatology
Peer Reviewed Journal
Visit Source
Visit Source
The American Journal of Clinical Nutrition
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Bone and Joint Surgery
Peer Reviewed Journal
Visit Source
Visit Source
Kidney International
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Allergy and Clinical Immunology
Peer Reviewed Journal
Visit Source
Visit Source
Annals of Surgery
Peer Reviewed Journal
Visit Source
Visit Source
Chest
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Neurology, Neurosurgery & Psychiatry
Peer Reviewed Journal
Visit Source
Visit Source
Blood
Peer Reviewed Journal
Visit Source
Visit Source
Gastroenterology
Peer Reviewed Journal
Visit Source
Visit Source
The American Journal of Respiratory and Critical Care Medicine
Peer Reviewed Journal
Visit Source
Visit Source
The American Journal of Psychiatry
Peer Reviewed Journal
Visit Source
Visit Source
Diabetes Care
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of the American College of Cardiology (JACC)
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Clinical Oncology (JCO)
Peer Reviewed Journal
Visit Source
Visit Source
Journal of Clinical Investigation (JCI)
Peer Reviewed Journal
Visit Source
Visit Source
Circulation
Peer Reviewed Journal
Visit Source
Visit Source
JAMA Internal Medicine
Peer Reviewed Journal
Visit Source
Visit Source
PLOS Medicine
Peer Reviewed Journal
Visit Source
Visit Source
Annals of Internal Medicine
Peer Reviewed Journal
Visit Source
Visit Source
Nature Medicine
Peer Reviewed Journal
Visit Source
Visit Source
The BMJ (British Medical Journal)
Peer Reviewed Journal
Visit Source
Visit Source
The Lancet
Peer Reviewed Journal
Visit Source
Visit Source
Journal of the American Medical Association (JAMA)
Peer Reviewed Journal
Visit Source
Visit Source
Pubmed
Comprehensive biomedical database
Visit Source
Visit Source
Harvard
Educational/Medical Institution
Visit Source
Visit Source
Cleveland Clinic
Educational/Medical Institution
Visit Source
Visit Source
Mayo Clinic
Educational/Medical Institution
Visit Source
Visit Source
The New England Journal of Medicine (NEJM)
Peer Reviewed Journal
Visit Source
Visit Source
Johns Hopkins
Educational/Medical Institution
Visit Source
Visit Source

Hey Practitioners! Ready to become a world class gut health expert? Join Jeannie Gorman, MS, CCN, for a Free Live Class that dives into how popular diets impact the gut microbiome, the clinical dietary needs of your gut, biomarkers to test to analyze gut health, and gain a clear understanding of the Doctor’s Data GI360™ profile. Register here.